Business, energy, technology, markets and global industry news from Business News Today

Munich

PharmaDeviceNews Munich
Editorial infographic highlighting Seaport Therapeutics’ GlyphAgo, with laboratory imagery, capsule medication, a liver graphic and a bioavailability chart, showing 6.8-fold higher bioavailability, advancing anxiety trials and the still-unproven potential to reduce liver risks.
Pharma & Biotech

Can Seaport’s GlyphAgo overcome agomelatine’s liver problem? New Phase 1 data sharpen the test

Seaport's GlyphAgo shows 6.8-fold higher bioavailability as anxiety trials advance, but its potential to reduce liver risks remains unproven.

Read More
Representative image: Scientists review antibody-drug conjugate research in an oncology laboratory as Gilead Sciences’ Tubulis acquisition sharpens focus on next-generation ADC platforms, solid tumour pipelines and cancer drug development strategy.
Pharma & Biotech

Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy

Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.

Read More